180 Life Sciences Corp. (NASDAQ: ATNF) in Hot Pursuit of New Anti-Inflammatory Blockbusters

Rhea-AI Summary

180 Life Sciences Corp. (NASDAQ: ATNF) has been featured in a NetworkNewsWire editorial titled "Controlling Inflammation to Stop Disease." This editorial highlights the significant link between inflammation and various health issues, which account for over 50% of global deaths. 180 Life Sciences is at the forefront of developing anti-inflammatory drugs, with its lead program in phase 2b/3 trials. The company is leveraging expertise from prestigious institutions like Oxford University and Stanford to create innovative therapies targeting unmet needs in inflammatory diseases, fibrosis, and pain.

Positive

• 180 Life Sciences is pioneering research in anti-inflammatory therapeutics with significant market potential.
• The company's lead program is currently in phase 2b/3 clinical trials, indicating progress towards market-ready solutions.

Negative

• None.

NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — 180 Life Sciences Corp. (NASDAQ: ATNF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

To view the full publication, “Controlling Inflammation to Stop Disease,” please visit: https://nnw.fm/VFpw9   

Inflammation has been directly linked to a wide variety of physical and mental health maladies. Inflammation is also a symptom of infectious diseases, implicated in noninfectious diseases, and new findings show a causal relationship with postsurgical trauma. Inflammatory diseases are recognized as the most significant cause of death in the world, with more than 50% of all deaths attributed to inflammation-related diseases. The recognition of the connection between inflammation and disease sparked a flurry of biotech research and a new generation of drug development to treat previously untreatable disorders.

World-renowned scientists that now lead 180 Life Sciences Corp. (NASDAQ: ATNF) pioneered the research and development of one of the first anti-inflammatory therapeutics to ever reach market, and today these drugs generate multiple billions of dollars in annual sales. Critical to creation of some the most important and profitable drugs ever on the market, the 180 team is in hot pursuit of new anti-inflammatory blockbusters with active programs in both preclinical and clinical studies.

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials.

For more information, visit the company’s website at www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://nnw.fm/ATNF

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness.

NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

FAQ

What is the recent editorial about 180 Life Sciences Corp. (ATNF)?

The editorial discusses the link between inflammation and health issues, featuring 180 Life Sciences' advancements in anti-inflammatory drug development.

What phase are 180 Life Sciences' clinical trials in?

The company’s lead program is in phase 2b/3 clinical trials, focusing on anti-inflammatory treatments.

How significant is inflammation in global health according to the editorial?

Inflammation is linked to over 50% of all global deaths, emphasizing the need for effective treatments.

Which prestigious institutions are involved with 180 Life Sciences?

180 Life Sciences collaborates with experts from Oxford University, the Hebrew University, and Stanford University.

Where can I find more information about 180 Life Sciences Corp. (ATNF)?

For additional information, visit 180 Life Sciences’ official website.